In the News
Pharma M&A Set To Boom in 2026, BioSpectrum Asia
January 31, 2026Partner Ning Zhang is featured in BioSpectrum Asia discussing the surge in life sciences mergers and acquisitions (M&A). “China’s biotech companies are increasingly recognised as key contributors to the global innovation ecosystem, and the trend of exporting innovation through out-licensing and M&A transactions is ever-increasing, with a number of landmark, multi-billion dollar deals in 2025,” said Ning.
He highlights China’s expanding influence in global biotech, noting, “I expect that such trends of out‑licensing and M&A activities involving China‑based biotech companies by leading global pharma companies will continue to boom in 2026.”